A pro-convulsive carbamazepine metabolite: Quinolinic acid in drug resistant epileptic human brain

Neurobiology of Disease

Volumn 46, Issue 3, 2012, Pages 692-700

  Ghosh, Chaitali ^a   Marchi, Nicola ^a   Hossain, Mohammed ^a   Rasmussen, Peter ^a   Alexopoulos, Andreas V ^a   Gonzalez Martinez, Jorge ^a   Yang, Hu ^b,c   Janigro, Damir ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Virginia Commonwealth University   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Blood brain barrier; Carbamazepine; Drug delivery; Drug metabolism; Drug resistance; In vitro models; Neurotoxicity; Pharmacogenomics; Pharmacokinetics; Tissue engineering

Indexed keywords

10,11 DIHYDRO 10,11 DIHYDROXYCARBAMAZEPINE; CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; CARBON 14; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; PREGABALIN; QUINOLINIC ACID; TOPIRAMATE;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG DETERMINATION; DRUG METABOLISM; DRUG RESPONSE; ENDOTHELIUM CELL; EPILEPSY; EX VIVO STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LOBECTOMY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; SCHOOL CHILD;

ADULT; ANTICONVULSANTS; BIOTRANSFORMATION; BRAIN CHEMISTRY; CARBAMAZEPINE; CHILD; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CONVULSANTS; DRUG RESISTANCE; ENDOTHELIAL CELLS; EPILEPSY; EPILEPSY, TEMPORAL LOBE; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; MODELS, NEUROLOGICAL; PRIMARY CELL CULTURE; QUINOLINIC ACID; REPRODUCIBILITY OF RESULTS;

EID: 84860838360     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.03.010     Document Type: Article

References (39)

1. Behan W.M.H., McDonald M., Darlington L.G., Stone T.W. Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl. Br. J. Pharmacol. 1999, 128:1754-1760.
2. Bordelon Y.M., Chesselet M.F., Nelson D., Welsh F., Erecinska M. Energetic dysfunction in quinolinic acid-lesioned rat striatum. J. Neurochem. 1997, 69:1629-1639.
3. Breton H., Cociglio M., Bressolle F., Peyriere H., Blayac J.P., Hillaire-Buys D. Liquid chromatography-electrospray mass spectrometry determination of carbamazepine, oxcarbazepine and eight of their metabolites in human plasma. J. Chromatogr. B 2005, 828:80-90.
4. Cucullo L., Hossain M., Rapp E., Manders T., Marchi N., Janigro D. Development of a humanized in vitro blood-brain barrier model to screen for brain penetration of antiepileptic drugs. Epilepsia 2007, 48:505-516.
5. Cucullo L., Couraud P.O., Weksler B., Romero I.A., Hossain M., Rapp E., Janigro D. Immortalized human brain endothelial cells and flow-based vascular modeling: a marriage of convenience for rational neurovascular studies. J. Cereb. Blood Flow Metab. 2008, 28:312-328.
6. Desai S.Y., Marroni M., Cucullo L., Krizanac-Bengez L., Mayberg M.R., Hossain M.T., Grant G.G., Janigro D. Mechanisms of endothelial survival under shear stress. Endothelium (New York) 2002, 9:89-102.
7. DiNatale B.C., Murray I.A., Schroeder J.C., Flaveny C.A., Lahoti T.S., Laurenzana E.M., Omiecinski C.J., Perdew G.H. Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. Toxicol. Sci. 2010, 115:89-97.
8. Dombrowski S.M., Desai S.Y., Marroni M., Cucullo L., Goodrich K., Bingaman W., Mayberg M.R., Bengez L., Janigro D. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 2001, 42:1501-1506.
9. During M.J., Freese A., Heyes M.P., Swartz K.J., Markey S.P., Roth R.H., Martin J.B. Neuroactive metabolites of L-tryptophan, serotonin and quinolinic acid, in striatal extracellular fluid - effect of tryptophan loading. FEBS Lett. 1989, 247:438-444.
10. Erhardt S., Olsson S.K., Engberg G. Pharmacological manipulation of kynurenic acid potential in the treatment of psychiatric disorders. CNS Drugs 2009, 23:91-101.
11. Fabene P.F., Mora G.N., Martinello M., Rossi B., Merigo F., Ottoboni L., Bach S., Angiari S., Benati D., Chakir A., Zanetti L., Schio F., Osculati A., Marzola P., Nicolato E., Homeister J.W., Xia L.J., Lowe J.B., Mcever R.P., Osculati F., Sbarbati A., Butcher E.C., Constantin G. A role for leukocyte-endothelial adhesion mechanisms in epilepsy. Nat. Med. 2008, 14:1377-1383.
12. Fedi M., Reutens D.C., Andermann F., Okazawa H., Boling W., White C., Dubeau F., Nakai A., Gross D.W., Andermann E., Diksic M. Alpha-[C-11]-methyl-L-tryptophan PET identifies the epileptogenic tuber and correlates with interictal spike frequency. Epilepsy Res. 2003, 52:203-213.
13. Fertig E.J.M.R.H. Carbamazepine. Epilepsy: A Comprehensive Textbook 2008, 1543-1555. Wolters-Kluwer, Philadelphia, PA. J. Engel, T.A. Pedley (Eds.).
14. Ghosh C., Gonzalez-Martinez J., Hossain M., Cucullo L., Fazio V., Janigro D., Marchi N. Pattern of P450 expression at the human blood-brain barrier: roles of epileptic condition and laminar flow. Epilepsia 2010, 51:1408-1417.
15. Ghosh C., Marchi N., Desai N.K., Puvenna V., Hossain M., Gonzalez-Martinez J., Alexopoulos A.V., Janigro D. Cellular localization and functional significance of CYP3A4 in the human epileptic brain. Epilepsia 2011, 52:562-571.
16. Ghosh C., Puvenna V., Gonzalez-Martinez J., Janigro D., Marchi N. Blood-brain barrier P450 enzymes and multidrug transporters in drug resistance: a synergistic role in neurological diseases. Curr. Drug Metab. 2011, 12:742-749.
17. Granata T., Marchi N., Carlton E., Ghosh C., Gonzalez-Martinez J., Alexopoulos A.V., Janigro D. Management of the patient with medically refractory epilepsy. Expert Rev. Neurother. 2009, 9:1791-1802.
18. Grant G.A., Abbott N.J., Janigro D. Understanding the physiology of the blood-brain barrier: in vitro models. News Physiol. Sci. 1998, 13:287-293.
19. Heyes M.P., Achim C.L., Wiley C.A., Major E.O., Saito K., Markey S.P. Human microglia convert L-tryptophan into the neurotoxin quinolinic acid. Biochem. J. 1996, 320:595-597.
20. Husain S., Khalid S., Nagaraju V., Rao R.N. High-performance liquid-chromatographic separation and determination of small amounts of process impurities of ciprofloxacin in bulk drugs and formulations. J. Chromatogr. A 1995, 705:380-384.
21. Ju C., Uetrecht J.P. Detection of 2-hydroxyiminostilbene in the urine of patients taking carbamazepine and its oxidation to a reactive iminoquinone intermediate. J. Pharmacol. Exp. Ther. 1999, 288:51-56.
22. Kocki T., Kocki J., Wielosz M., Turski W.A., Urbanska E.M. Carbamazepine enhances brain production of kynurenic acid in vitro. Eur. J. Pharmacol. 2004, 498:325-326.
23. Kwan P., Schachter S.C., Brodie M.J. Current concepts drug-resistant epilepsy. N. Engl. J. Med. 2011, 365:919-926.
24. Loscher W., Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat. Rev. Neurosci. 2005, 6:591-602.
25. Marchi N., Fan Q.Y., Ghosh C., Fazio V., Bertolini F., Betto G., Batra A., Carlton E., Najm I., Granata T., Janigro D. Antagonism of peripheral inflammation reduces the severity of status epilepticus. Neurobiol. Dis. 2009, 33:171-181.
26. Marchi N., Gonzalez-Martinez J., Nguyen M.T., Granata T., Janigro D. Transporters in drug-refractory epilepsy: clinical significance. Clin. Pharmacol. Ther. 2010, 87:13-15.
27. Marchi N., Teng Q.S., Ghosh C., Fan Q.Y., Nguyen M.T., Desai N.K., Bawa H., Rasmussen P., Masaryk T.K., Janigro D. Blood-brain barrier damage, but not parenchymal white blood cells, is a hallmark of seizure activity. Brain Res. 2010, 1353:176-186.
28. Natsume J., Kumakura Y., Bernasconi N., Soucy J.P., Nakai A., Rosa P., Fedi M., Dubeau F., Andermann F., Lisbona R., Bernasconi A., Diksic M. Alpha-[C-11] methyl-L-tryptophan and glucose metabolism in patients with temporal lobe epilepsy. Neurology 2003, 60:756-761.
29. Potschka H., Fedrowitz M., Loscher W. P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. Neuroreport 2001, 12:3557-3560.
30. Raison C.L., Dantzer R., Kelley K.W., Lawson M.A., Woolwine B.J., Vogt G., Spivey J.R., Saito K., Miller A.H. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol. Psychiatry 2010, 15:393-403.
31. Rambeck B., Jurgens U.H., May T.W., Pannek H.W., Behne F., Ebner A., Gorji A., Straub H., Speckmann E.J., Pohlmann-Eden B., Loscher W. Comparison of brain extracellular fluid, brain tissue, cerebrospinal fluid, and serum concentrations of antiepileptic drugs measured intraoperatively in patients with intractable epilepsy. Epilepsia 2006, 47:681-694.
32. Santaguida S., Janigro D., Hossain M., Oby E., Rapp E., Cucullo L. Side by side comparison between dynamic versus static models of blood-brain barrier in vitro: a permeability study. Brain Res. 2006, 1109:1-13.
33. Schwarcz R., Speciale C., French E.D. Hippocampal kynurenines as etiological factors in seizure disorders. Pol. J. Pharmacol. Pharm. 1987, 39:485-494.
34. Smith D.G., Guillemin G.J., Pemberton L., Kerr S., Nath A., Smythe G.A., Brew B.J. Quinolinic acid is produced by macrophages stimulated by platelet activating factor, Nef and Tat. J. Neurovirol. 2001, 7:56-60.
35. Stone T.W., Darlington L.G. Endogenous kynurenines as targets for drug discovery and development. Nat. Rev. Drug Discov. 2002, 1:609-620.
36. Stone T.W., Perkins M.N. Quinolinic acid - a potent endogenous excitant at amino-acid receptors in CNS. Eur. J. Pharmacol. 1981, 72:411-412.
37. Tompkins E.M., Farmer P.B., Lamb J.H., Jukes R., Dingley K., Ubick E., Turteltaub K.W., Martin E.A., Brown K. A novel C-14-postlabeling assay using accelerator mass spectrometry for the detection of O-6-methyldeoxy-guanosine adducts. Rapid Commun. Mass Spectrom. 2006, 20:883-891.
38. Wu Q., Zhang Y.-H., Zhao X., Shi W.-L., Pu X.-P. Proteome studies on liver tissue in a phenobarbital-induced rat model. Eur. J. Pharmacol. 2011, 670:333-340.
39. Zhang X.Q., He Y., Ding M. Simultaneous determination of tryptophan and kynurenine in plasma samples of children patients with Kawasaki disease by high-performance liquid chromatography with programmed wavelength ultraviolet detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2009, 877:1678-1682.